Remove 2020 Remove Chemotherapy Remove Labelling
article thumbnail

BMS will file for earlier-line use of Breyanzi in lymphoma after trial win

pharmaphorum

Now, results from the ongoing TRANSFORM study show that Breyanzi was more effective than the standard second-line treatment – salvage therapy followed by high-dose chemotherapy and a stem cell transplant – at fending off disease recurrence.

article thumbnail

ASH: Trial backs Gilead’s Yescarta CAR-T in first-line lymphoma

pharmaphorum

The 40-patient open-label study is the first to evaluate CAR-T therapy in treatment-naïve in high-risk LBCL, which is currently treated first-line mainly with rituximab and a chemo regimen known as CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone). billion. .

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

ADC shrinks brain metastases in HER2+ breast cancer patients

European Pharmaceutical Review

The prospective, open-label, single-arm, Phase II TUXEDO-1 study enrolled 14 women and one man with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and newly diagnosed untreated brain metastases or brain metastases progressing after previous local therapy.

article thumbnail

Y-mAbs claims FDA OK for neuroblastoma drug Danyelza

pharmaphorum

Danyelza has been granted accelerated approval by the FDA on the strength of two open-label phase 2 studies. And combination trials with chemotherapy are also planned. Progression-free survival and overall survival are secondary endpoints in long-term follow-up, with the data not yet available.

FDA 105
article thumbnail

PARP rivals close in on AZ and Merck’s market leading Lynparza

pharmaphorum

This week has seen two readouts for rivals from Clovis Oncology and Pfizer in prostate cancer – one of several indications on the Lynparza (olaparib) label – that could lead to a challenge to the $3 billion blockbuster.

article thumbnail

FDA clears new first-line use for Servier’s Tibsovo in AML

pharmaphorum

The US regulator has approved Tibsovo (ivosidenib) in combination with Bristol-Myers Squibb’s chemotherapy Vidaza (azacitidine) as a first-line therapy for IDH1-mutated acute myeloid leukaemia (AML), expanding the eligible patient population for the drug. for the Tibsovo arm and 14.9% for the control group.

FDA 52
article thumbnail

Who should not take probiotics?

The Checkup by Singlecare

If your immune system is compromised due to medication, chemotherapy, or radiation therapy, probiotics may increase the risk of developing a bacterial or fungal infection. Anyone with food allergies should thoroughly review the label, research the company, and consult their allergist or healthcare provider before taking probiotics.